--- title: "Replimune | 8-K: FY2027 Q1 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/295932765.md" datetime: "2026-08-14T12:12:54.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295932765.md) - [en](https://longbridge.com/en/news/295932765.md) - [zh-HK](https://longbridge.com/zh-HK/news/295932765.md) generator: "portal-rs" --- # Replimune | 8-K: FY2027 Q1 Revenue: USD 0 Revenue: As of FY2027 Q1, the actual value is USD 0. EPS: As of FY2027 Q1, the actual value is USD -0.72, missing the estimate of USD -0.699. EBIT: As of FY2027 Q1, the actual value is USD -69.15 M. Replimune Group, Inc. reported financial results for the fiscal first quarter ended June 30, 2026, which included the U.S. Food and Drug Administration (FDA) approval of TUDRIQEV (vusolimogene oderparepvec-wtpg), previously RP1, in combination with nivolumab for adults with unresectable advanced cutaneous melanoma who experienced disease progression with a PD-1 antibody-based regimen. The company has commenced launch preparations in the U.S. and expects TUDRIQEV to be in the market within 60 days. Replimune Group, Inc. also completed a $150 million financing to support the commercial launch and the ongoing IGNYTE-3 confirmatory trial. Michelle DiNapoli was appointed Chief Commercial Officer, effective August 18, 2026. #### Operational Metrics - **IGNYTE-3 Confirmatory Study (RP1):** The global Phase 3 trial assessing RP1 in combination with nivolumab for advanced melanoma is actively enrolling, with the primary endpoint expected to readout in 2030. - **REVEAL Study (RP2):** The registration-directed Phase 2⁄3 trial of RP2 in metastatic uveal melanoma is actively enrolling, with Phase 2⁄3 transition anticipated in Q1 2027. #### Cash Position As of June 30, 2026, cash, cash equivalents, and short-term investments totaled $195.3 million, a decrease from $268.9 million as of March 31, 2026. This decrease was attributed to cash burn from operating activities related to advancing clinical development plans. #### Operating Expenses - **Research and Development (R&D) Expenses:** R&D expenses were $49.3 million for the fiscal first quarter ended June 30, 2026, down from $57.8 million for the fiscal first quarter ended June 30, 2025. This decrease was primarily due to lower personnel and other costs, as well as reduced direct research costs for the IGNYTE, ARTACUS, and CERPASS studies. R&D expenses included $3.6 million in stock-based compensation for the fiscal first quarter ended June 30, 2026. - **Selling, General and Administrative (S,G&A) Expenses:** S,G&A expenses were $19.0 million for the fiscal first quarter ended June 30, 2026, compared to $32.6 million for the fiscal first quarter ended June 30, 2025. S,G&A expenses included $4.1 million in stock-based compensation for the fiscal first quarter ended June 30, 2026. - **Total Operating Expenses:** Total operating expenses for the fiscal first quarter ended June 30, 2026, were $68.2 million, a decrease from $90.4 million for the same period in 2025. #### Loss from Operations Loss from operations was - $68.2 million for the fiscal first quarter ended June 30, 2026, compared to - $90.4 million for the fiscal first quarter ended June 30, 2025. #### Other Income (Expense) Total other expense, net, was - $1.5 million for the fiscal first quarter ended June 30, 2026, compared to $3.7 million for the fiscal first quarter ended June 30, 2025. This included research and development incentives of $0.3 million in 2026 versus $0.4 million in 2025, investment income of $2.0 million in 2026 versus $4.7 million in 2025, interest expense on finance lease liability of - $0.5 million in 2026 versus - $0.5 million in 2025, interest expense on debt obligations of - $2.6 million in 2026 versus - $1.5 million in 2025, and other expense, net, of - $0.7 million in 2026 versus $0.6 million in 2025. #### Net Loss Net loss was - $69.8 million for the fiscal first quarter ended June 30, 2026, an improvement from - $86.7 million for the fiscal first quarter ended June 30, 2025. #### Balance Sheet Data (as of June 30, 2026 vs. March 31, 2026) - **Working Capital:** $162.4 million versus $220.9 million. - **Total Assets:** $252.4 million versus $332.4 million. - **Total Stockholders’ Equity:** $105.6 million versus $166.2 million. #### Outlook / Guidance Replimune Group, Inc. expects its existing cash, cash equivalents, and short-term investments as of June 30, 2026, combined with $141.0 million in net proceeds from a common stock issuance in August 2026, to fund operations for over twelve months. This funding is intended to support the scale-up for commercialization of TUDRIQEV in advanced melanoma, as well as general working capital and corporate purposes. The ability to maintain TUDRIQEV’s accelerated approval and continue commercialization may depend on verification of clinical benefit in confirmatory trials. ### Related Stocks - [REPL.US](https://longbridge.com/en/quote/REPL.US.md) ## Related News & Research - [16:20 ETRobbins LLP Urges REPL Investors Who Lost Money Investing in Replimune to Contact the Firm for Information About Leading the Class Action](https://longbridge.com/en/news/296649920.md) - [Quantinno Capital Management LP Increases Stock Position in Replimune Group, Inc. $REPL](https://longbridge.com/en/news/296198190.md) - [Replimune grants CCO Michelle DiNapoli options for 150,000 shares at $15.58, plus 100,000 RSUs](https://longbridge.com/en/news/296394220.md) - [Replimune FY27 Q1 net loss narrows to $69.8 million; R&D expenses fall to $49.3 million](https://longbridge.com/en/news/295931365.md) - [FN: Record revenue and EPS growth in Q4 and FY26, with strong outlook for Q1 FY27](https://longbridge.com/en/news/296142824.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**